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ABSTRACT
Objective: The assessment of neopterin and interferon-gamma (IFN-γ) levels as a part of immune system response about serum iron status in 
β-thalassemia (TM) major patients.
Methods: Spectrophotometry applied for the estimation of iron status including serum iron level, total iron-binding capacity, and unsaturated iron-
binding capacity. Enzyme-linked immunosorbent assay (ELISA) applied for the estimation of the serum cytokines included neopterin and IFN-γ also 
serum ferritin estimation by ELISA from 130 β-TM major patients where they divided according to serum ferritin level (< and ≥2500 ng/mL).
Results: The neopterin and IFN-γ concentration showed significantly increased with direct correlation among TM patient group when compared to 
the normal healthy control group. However, there was no significant difference between different levels of serum ferritin.
Conclusion: The increased serum level of neopterin and IFN-γ found in patients with β-TM may be due to the direct effect of iron on cellular immune cells beside 
of immune system response to the effect of iron toxicity on different body organs. There was a direct moderate relationship between neopterin and IFN-γ.
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INTRODUCTION
The hereditary anemia β-thalassemia (β-TM) characterized by 
defects in the production of the β-globin chains [1]. The ineffective 
erythropoiesis in β-TM is due to defective hemoglobin synthesis, 
which leads to severe anemia, increased erythrocyte turnover, and 
excessive iron absorption [2]. Neopterin is a compound isolated from 
the larvae of bees, from worker bees, and from royal jelly [3,4]. It 
is a 2-amino-4-–hydroxy-(1,2,3-trihydroxypropyl)-pteridine with a 
low molecular mass (253 Da). In humans, it is produced by activated 
monocytes/macrophages from guanosine triphosphate (GTP) 
through GTP cyclohydrolase I. The activity of this enzyme is greatly 
enhanced by interferon-gamma (IFN-γ) and, to a lesser degree, by 
IFN-α, other cytokines, and endotoxins [5,6]. A wide spectrum of 
immune abnormalities has described in reports of numerous studies 
on patients with β-TM who have iron overload [7]. The abnormalities 
observed to date are both quantitative and functional and involve 
several components of the immune response [8]. The susceptibility 
to infections found in both splenectomised and non- splenectomised 
patients; which caused by the interaction of excess free iron with cells 
of the immune system as consequence of iron overload [9].
It has suggested that a variety of factors, including non-splenectomy, 
iron overload, repeated exposure to foreign antigens at the time 
of blood transfusion, and the use of chelating agents, may induce 
profound deleterious effects on the immune system [10]. An increase 
in the serum level of neopterin associated with diseases involving the 
cellular immune response [11]. In Iraqi, still there is no awareness 
about the effect of iron overload in immunity status beside overall the 
world, there is still debate on this issue as some of articles say that 
there is suppression of immune system in iron overload and other said 
that there is stimulation of immune system through immunogenicity 
of body tissue in TM major patients. The aim of this study was to the 
evaluation of neopterin and IFN-γ as a part of body immune system 
response about serum iron status with β-TM major patients in Baghdad 
Medical City Hospital.
METHODS
This prospective study was carried out on 130 blood transfusion-
dependent patients with TM major (non-splenectomized), mean age 
(year) was 13.56 ± 4.72. The study includes three groups: The first 
group was 65 TM patients with serum ferritin <2500 ng/mL (Group A), 
65 TM patients with serum ferritin ≥2500 ng/mL (Group B), while 
Group C was 65 persons’ healthy subjects as a control group. All patients 
selected had no clinical history of recent infection, fever, DM, and viral 
hepatitis infection. The serum levels of ferritin, neopterin, and IFN-γ 
were assayed by enzyme-linked immunosorbent assay (ELISA) (Reader 
and Printer Systems, USA) and ELISA (Washer system, Australia); iron 
status levels were assessed by spectrophotometry (Ce Cecil, England) 
for all three groups.
Written informed consent obtained from all patients, the study was 
approved by the Ethical Committee from College Science for Women/
University of Baghdad and was in accordance with Helsinki declaration 
for clinical research.
Statistical analyses were conducted using the statistical software 
package of SPSS version 20.0.0. Differences between groups were 
assessed by the Mann–Whitney U-test for non-parametric variables. 
Pearson’s correlation coefficients were calculated to evaluate the 
association between relevant parameters. Statistical significance was 
set at p<0.05.
RESULTS
As in Table 1, there was the statistically significant difference in serum 
iron status levels including serum iron, total iron bounding capacity “total 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i9.26661
Research Article
193
Asian J Pharm Clin Res, Vol 11, Issue 9, 2018, 192-194
 Obeid et al. 
iron-binding capacity [TIBC],” unsaturated iron-binding capacity [UIBC], 
and serum ferritin among the studied and control groups with p<0.001.
There was the statistically significant difference (p<0.001) found 
among all studied TM patients with high serum level of neopterin and 
IFN-γ concentration when compared to the healthy control group, as 
illustrated in Table 2.
In Fig. 1, there is a direct moderate significant correlation (r=0.517, 
p<0.001) between IFN-γ level and neopterin parameters within TM 
patients group.
The results in Table 3 showed the correlation between neopterin and 
serum ferritin level. Serum level of neopterin correlated strongly and 
positively (p<0.001) with serum ferritin (r=0.648) in all thalassemic 
patient’s; however, this relationship became weak and non-significant 
after we divided the serum ferritin level into two groups (using 
2500 ng/mL as a cut point), as illustrated in Table 3.
Again the results in Table 4 showed the correlation between IFN-γ and 
serum ferritin level. Serum level of IFN-γ moderately and positively 
correlated (p<0.001) with serum ferritin (r=0.483) in all thalassemic 
patient’s; however, this relationship became weak and non-significant 
after we divided the serum ferritin level into two groups (using 
2500 ng/mL as cut point), as illustrated in Table 4.
DISCUSSION
Our body developed the capacity to modulate cellular iron metabolism 
not only for its optimal utilization as a catalyst for the generation of 
reactive oxygen species acting as strong antimicrobial molecules but 
also to make iron less available for the microorganisms [12,13], from 
this concept, the current study established trying to understand effect 
of iron overload on immune system. Here, in our studied TM patients 
group had significantly higher iron body status, as serum level of iron 
was significantly higher in thalassemic patients compared to healthy 
control (209.3±70.3 vs. 70.26±6.25), TIBC was significantly higher in 
thalassemic patients compared to healthy control (627.9±210.9 vs. 
210.79±18.75), UIBC was significantly higher in thalassemic patients 
compared to healthy control (74.9±25.2 vs. 25.15±2.24), and serum 
ferritin was significantly higher in thalassemic patients compared to 
healthy control (3439.5±2299 vs. 70.94±15.82) also. This findings of 
the current study were in agreement with Ayoub et al., [14] Hadeed 
et al., [15] and Abdulzahra et al. [16] studies. Iron overload is common in 
TM major, and it is responsible for many of the other complications that 
occur in these disorders. Iron overload may result from a combination 
of ineffective erythropoiesis, which promotes increased intestinal 
iron uptake, and due to frequent blood transfusion because of chronic 
anemia. The contribution of ineffective erythropoiesis is significant.
In the current study, serum IFN-γ was significantly increased in 
thalassemic patients compared to control group (38.6±10.5 vs. 
5.55±1.70) p<0.001, and as iron overload increases, the IFN-γ 
significantly became higher (45.01±7.54 vs. 32.09±8.90, p<0.001); in 
both high and low iron overload, respectively, which may be due to 
activation of the immune system because of the direct effect of iron on 
different body organs including cellular immunity causing activation 
of monocular cells and increase of IFN-γ, and other relaying cytokines 
even in the absence of secondary infection [17]. Our finding was in 
agreement with Salsaa and Zoumbos in which they found that IFN-γ 
produced more among TM patients compared to control [18], while in 
another Iranian study, Gharagozloo et al. reported the opposite in which 
IFN-γ was lower in TM patients, they attributed these controversial 
findings to selection of their patients in which their patients did not 
have infections nor any acute or chronic disease that may affect IFN-γ 
serum levels, although our study also excluded the presence of infection 
or chronic disease before including the patients in the study [2]. 
A difference in the exclusion criteria in the current study compared to 
the above studies leads to this variation in IFN-γ levels.
Again the serum level of neopterin was also significantly higher in TM 
patients compared to control (7.25±3.23 vs. 1.27±0.65, p<0.001), and 
among high iron overload group compared to low iron overload group 
(9.83±2.62 vs. 4.67±0.83, p<0.001) too. Our findings were in agreement 
with Shanab et al. (2014) 19.0 versus 9.0 mmoL/L [19]. The IFN-γ is 
responsible for stimulation of neopterin synthesis (a catabolic product 
of GTP) and then produced by macrophages indicating its role as a 
marker for cellular immunity activation [20,21]. In the current study, 
we found a direct strong correlation between both neopterin and IFN-γ 
(r=0.517, p<0.001) in TM patients, which is in agreement with previous 
studies [20,21] since IFN-γ is the most potent activator of neopterin 
production in human cells, this explains why both were elevated in 
Fig. 1: Correlation between serum levels of Interferon-gamma 
versus neopterin in all thalassemic patients (n=130)
Table 1: Iron study analysis among different studied groups
Variables Healthy individuals (n=65) All thalassemic (n=130) p value
Iron (µmol/L), mean±SD 70.26±6.25 209.3±70.3 <0.001
TIBC, mean±SD 210.79±18.75 627.9±210.9 <0.001
UIBC, mean±SD 25.15±2.24 74.9±25.2 <0.001
Ferritin (ng/mL), mean±SD 70.94±15.82 3439.5±2299 <0.001
TIBC: Total iron-binding capacity, UIBC: Unsaturated iron-binding capacity
Table 2: Assessment of neopterin and IFN -γ among the studied groups
Variables Healthy individuals (n=65) All thalassemic (n=130) p value
IFN‑γ (pg/mL), mean±SD 5.54±1.70 38.55±10.47 <0.001
Neopterin (ng/mL), mean±SD 1.27±0.65 7.25±3.23 <0.001
IFN‑γ: Interferon-gamma
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TM patients group. As neopterin has an indirect inhibitory effect on 
erythropoiesis, as some studies suggested when it added to a perfusion 
fluid, neopterin causes a decrease in erythropoietin mRNA levels [20] 
so that we should be aware of other causes of anemia in TM patients 
which may help to decrease the frequency of blood transfusion beside 
strict control of iron level with serum ferritin lower than 1000 ng/mL.
RECOMMENDATION
The increased serum level of neopterin and IFN-γ found in patients with 
β-TM may be due to effects of iron overload on immune system cells and 
other damaged body organs causing activation and releasing different 
cytokines and immune markers regardless the presence of infection.
We recommend studying the neopterin level in patients with TM major 
patients with <1000 ng/mL, and its relation to the frequency of blood 
transfusion in major TM patients.
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All patients 0.648 <0.001
Ferritin<2500 0.225 0.071
Ferritin≥2500 0.122 0.334
r: Pearson’s correlation coefficient
Table 4: Correlation between IFN-γ and serum ferritin levels
Variable IFN-γ (pg/mL)
r p value
All patients 0.0483 <0.001
Ferritin<2500 ng/mL 0.235 0.059
Ferritin≥2500 ng/mL 0.007 0.953
r: Pearson’s correlation coefficient, IFN-γ: Interferon-gamma
